SWITZERLAND —Swiss bioprocess analytics provider DataHow has secured an extension to its Series A financing round through a bridge capital injection. The investment was led by industrial impact venture capital firm Momenta, alongside existing backers Rockwell Automation, HINA Bioventures, and Zürcher Kantonalbank. Based in Zurich, Switzerland, DataHow is a technology spin-off specializing in AI-driven data modeling and digital twin solutions designed to optimize biopharmaceutical research and manufacturing workflows.
The newly acquired capital is targeted at expanding the operational scope of DataHowLab, the company's core software platform. Key development milestones include integrating real-time software connections to lab hardware and manufacturing units, introducing automated model-based process guidance, and broadening analytical coverage from upstream unit operations to downstream purification steps. These enhancements aim to create a single digital intelligence environment spanning the entire bioprocessing life cycle.
This capital expansion highlights a broader transformation within life sciences manufacturing, where companies are increasingly replacing traditional retrospective data analysis with real-time, predictive modeling. Integrating artificial intelligence directly into production lines enables automated disturbance rejection and dynamic process optimization, helping biopharmaceutical operators decrease experimental timelines, improve batch consistency, and lower overall operational expenses.
From a strategic standpoint, the capital extension strengthens alliances between specialized software providers and established industrial automation entities like Rockwell Automation. For life sciences enterprises and investors, the shift toward autonomous manufacturing infrastructure offers a scalable path to shorten drug development cycles, manage complex biologic therapies, and enhance yield predictability across global supply chains.
